This trial is evaluating whether Durvalumab will improve 1 primary outcome and 4 secondary outcomes in patients with Portal Hypertension. Measurement will happen over the course of Treatment, and up to 30 days post transplant.
This trial requires 30 total participants across 1 different treatment group
This trial involves a single treatment. Durvalumab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"While there appear to be higher risks associated with lifetime exposure to tobacco smoke, past history of alcohol abuse, and family history of pancreatic disease, risk factors do not completely explain the occurrence of pancreatic cancer. Further research into the etiology of pancreatic cancer is needed to better understand how risk factors contribute to development of this disease and the polygenic nature of its causation." - Anonymous Online Contributor
"In the United States, inpatient mortality from cancer in persons aged 65 years or older was approximately 1% for all causes during 1995 through 1999. But overall mortality from cancer among persons aged 65 years or older was 4.3% (95% confidence interval 3.8-4.7%). Cancers with the highest rates of death were lung cancer, breast cancer, colorectal cancer, and liver cancer in men; and lung cancer, cervical cancer, breast cancer, colorectal cancer, and ovarian cancer in women." - Anonymous Online Contributor
"Durvalumab is an anti-PD-1 antibody approved by the FDA for the treatment of metastatic melanoma. There are currently no specific recommendations on the use of durvalumab for any other cancer type. In addition, there are no studies on the use of durvalumab in patients with other cancers such as lung cancer, head and neck cancer, colorectal cancer, or renal cell carcinoma. Given the limited number of eligible studies, the current evidence suggests that durvalumab should be used cautiously for patients with solid tumors and those who have received prior therapy (mainly immunotherapy and chemotherapy), due to the risk of severe immune-suppression." - Anonymous Online Contributor
"Recent findings suggest that tumors that spread later have fewer lymph nodes involved (LN-) when compared with LN+ tumors. This suggests that the extent of tumor spread into regional lymph nodes influences survival and may affect the usefulness of the current staging system." - Anonymous Online Contributor
"Carcinoma occurs more frequently among whites than blacks (1.4% versus 0.7%) or Hispanics (0.8% versus 0.5%), but the severity of the disease varied little among races." - Anonymous Online Contributor
"The overall safety profile of durvalumab was acceptable In a recent study population with metastatic colorectal cancer. Durvalumab showed efficacy and quality of life benefits when added to standard care in this group of patients." - Anonymous Online Contributor
"As we have shown, there has been much progress in the field of carcinoma research. Higher levels of P53 expression correlate with lower DFS, higher levels of EGFR expression correlate with worse survival, and high levels of MMP-7 expression correlate with poor overall survival. There also appears to be a correlation between the progression of stages and the corresponding changes in gene expression. These data suggest that there may be a role for targeted therapies in mcn cancers." - Anonymous Online Contributor
"The cause of carcinoma is not clear but is believed to involve environmental factors such as smoking, alcohol, infections with HPV and hepatitis B virus, and metabolic changes due to obesity and type 2 diabetes. There is some evidence that genetics plays a role.\n\nThe Mayo Clinic Cancer Center conducts clinical trials at all three Mayo campuses in Rochester, Minnesota; Jacksonville, Florida; and Phoenix, Arizona. It is one of only two comprehensive cancer centers in Western New York.\n\nThe Center has been a member of the American College of Surgeons' National Surgical Quality Improvement Program since 2006 and was granted full accreditation in 2016." - Anonymous Online Contributor
"The most common adverse events occurring in ≥1% of patients treated with durvalumab were fatigue (60%), upper respiratory tract infection (11%), pneumonitis (8%), nausea (7%), dyspnoea (6%), diarrhoea (5%), headache (5%), myalgia (5%) and constipation (4%). Patients receiving durvalumab had similar rates of severe adverse events compared to those receiving placebo. In contrast, patients receiving sorafenib (marketed as Nexavar® for hepatocellular carcinoma), an anti-angiogenic agent used to treat HCC (hepatatic carcinoma), experienced more serious adverse events than patients taking placebo." - Anonymous Online Contributor
"The word carcinoma is derived from the Greek "karkinos" meaning “a sore” or “a ulcer”, and "oma", meaning “disease, tumour”. This term was used because tumors were thought to arise due to an inflammation caused by a disease that had already begun. Because of this confusion, other terms (such as cancerous neoplasm) were sometimes used to describe tumors. These terms are still commonly used today to describe malignant tumors. \n\nCarcinoma is not a single entity; rather, there are several different types of cancer that are either true cancers or pseudo-cancers." - Anonymous Online Contributor